股本结构
单位：万股
| 公告日期 | 2026-02-24 | 2026-02-24 | 2025-10-28 | 2025-10-28 | 2025-07-29 | 2025-07-29 |
|---|---|---|---|---|---|---|
| 证券总股本 | 7653.54 | 7629.42 | 7579.58 | 7542.47 | 7410.77 | 7403.24 |
| 普通股本 | 7653.54 | 7629.42 | 7579.58 | 7542.47 | 7410.77 | 7403.24 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-02-20 | 2025-12-31 | 2025-10-24 | 2025-09-30 | 2025-07-25 | 2025-06-30 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-02-24 | 7653.54 | 未披露 | 定期报告 | 2026-02-20 |
| 2026-02-24 | 7629.42 | 未披露 |
更多>>
From December 31, 2024 to December 31, 2025
Issuance of Class A ordinary shares under incentive award plans and employee share purchase plan
|
2025-12-31 |
| 2025-10-28 | 7579.58 | 未披露 | 定期报告 | 2025-10-24 |
| 2025-10-28 | 7542.47 | 未披露 |
更多>>
From June 30, 2025 to September 30, 2025
Issuance of Class A ordinary shares under incentive award plans
|
2025-09-30 |
| 2025-07-29 | 7410.77 | 未披露 | 定期报告 | 2025-07-25 |
| 2025-07-29 | 7403.24 | 未披露 |
更多>>
From March 31, 2025 to June 30, 2025
Issuance of Class A ordinary shares under incentive award plans
|
2025-06-30 |
| 2025-04-29 | 7297.10 | 未披露 | 定期报告 | 2025-04-25 |
| 2025-04-21 | 7294.95 | 未披露 | 定期报告 | 2025-04-08 |
| 2025-04-29 | 7279.73 | 未披露 |
更多>>
From December 31, 2024 to March 31, 2025
Issuance of Class A ordinary shares under incentive award plans
|
2025-03-31 |
| 2025-02-25 | 7264.42 | 未披露 | 定期报告 | 2025-02-21 |
| 2025-02-25 | 7251.61 | 未披露 |
更多>>
From December 31, 2023 to December 31, 2024
Issuance of Class A ordinary shares under incentive award plans and employee share purchase plan
|
2024-12-31 |
| 2024-10-29 | 7220.16 | 未披露 | 定期报告 | 2024-10-25 |
| 2024-10-29 | 7215.82 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Issuance of Class A ordinary shares under incentive award plans
|
2024-09-30 |
| 2024-07-25 | 7124.37 | 未披露 | 定期报告 | 2024-07-19 |
| 2024-06-28 | 7108.23 | 未披露 | 定期报告 | 2024-06-28 |
| 2024-04-25 | 7094.01 | 未披露 | 定期报告 | 2024-04-19 |
| 2024-04-23 | 7093.92 | 未披露 | 定期报告 | 2024-04-15 |
| 2024-04-25 | 7081.91 | 未披露 |
更多>>
From December 31, 2023 to March 31, 2024
Issuance of Class A common shares under incentive award plans
|
2024-03-31 |
| 2024-02-28 | 7061.50 | 未披露 | 定期报告 | 2024-02-23 |
| 2024-02-28 | 7046.06 | 未披露 |
更多>>
From December 31, 2022 to December 31, 2023
Issuance of Class A common shares under incentive award plans and employee share purchase plan
|
2023-12-31 |
| 2023-11-02 | 7033.84 | 未披露 | 定期报告 | 2023-10-27 |
| 2023-11-02 | 7031.66 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Issuance of Class A common shares under incentive award plans
|
2023-09-30 |
| 2023-08-01 | 7016.69 | 未披露 | 定期报告 | 2023-07-28 |
| 2023-08-01 | 7000.27 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Issuance of Class A common shares under incentive award plans
|
2023-06-30 |
| 2023-05-04 | 6989.95 | 未披露 | 定期报告 | 2023-04-30 |
| 2023-04-27 | 6989.88 | 未披露 | 定期报告 | 2023-04-10 |
| 2023-05-04 | 6983.31 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Issuance of Class A common shares under incentive award plans
|
2023-03-31 |
| 2023-03-02 | 6975.31 | 未披露 | 定期报告 | 2023-02-28 |
| 2023-03-02 | 6969.75 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Issuance of Class A common shares under incentive award plans and employee share purchase plan
|
2022-12-31 |
| 2022-11-03 | 6953.18 | 未披露 | 定期报告 | 2022-10-31 |
| 2022-11-03 | 6952.43 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Issuance of Class A common shares under incentive award plans
|
2022-09-30 |
| 2022-08-04 | 6947.11 | 未披露 | 定期报告 | 2022-07-31 |
| 2022-08-04 | 6942.68 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Issuance of Class A common shares under incentive award plans
|
2022-06-30 |
| 2022-05-05 | 6927.57 | 未披露 | 定期报告 | 2022-04-30 |
| 2022-04-28 | 6927.36 | 未披露 | 定期报告 | 2022-04-14 |
| 2022-05-05 | 6927.11 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
Issuance of Class A common shares under incentive award plans
|
2022-03-31 |
| 2022-02-24 | 6910.44 | 未披露 | 定期报告 | 2022-01-31 |
| 2022-02-24 | 6906.04 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of Class A common shares under incentive award plans and employee share purchase plan
|
2021-12-31 |
| 2021-11-04 | 6888.84 | 未披露 | 定期报告 | 2021-10-31 |
| 2021-11-04 | 6888.84 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Issuance of Class A common shares under incentive award plans and employee share purchase plan
|
2021-09-30 |
| 2021-08-05 | 6852.31 | 未披露 | 定期报告 | 2021-07-31 |
| 2021-08-05 | 6846.47 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Issuance of Class A common shares under incentive award plans
|
2021-06-30 |
| 2021-05-06 | 6833.20 | 未披露 | 定期报告 | 2021-04-30 |
| 2021-04-28 | 6833.20 | 未披露 | 定期报告 | 2021-04-15 |
| 2021-05-06 | 6833.00 | 未披露 |
更多>>
From December 31, 2020 to March 31, 2021
Issuance of Class A common shares under incentive award plans
|
2021-03-31 |
| 2021-02-25 | 6823.23 | 未披露 | 定期报告 | 2021-01-31 |
| 2021-02-25 | 6821.50 | 未披露 |
更多>>
From December 31,2019 to December 31,2020
Issuance of Class A common shares upon completion of follow-on offerings, inclusive of the over-allotment option exercise, net of underwriting discounts and commissions and other offering costs
Issuance of Class A1 common shares upon completion of private placements, net of placement agent fees
Issuance of Class A common shares in connection with the release of escrow from the acquisition of all issued and outstanding equity securities of Primatope Therapeutics, Inc.
Issuance of Class A common shares under incentive award plans and employee share purchase plan
|
2020-12-31 |
| 2020-11-05 | 6807.50 | 未披露 | 定期报告 | 2020-10-31 |
| 2020-11-05 | 6791.73 | 未披露 |
更多>>
from June 30, 2020 to September 30, 2020
Issuance of Class A common shares upon completion of follow-on offering, net of underwriting discounts and commissions and other offering costs
Issuance of Class A1 common shares upon completion of private placement, net of placement agent fees
Issuance of Class A common shares in connection with the release of shares in connection with a milestone previously paid to Primatope Therapeutics, Inc.
Exercise of options
|
2020-09-30 |
| 2020-08-04 | 6787.39 | 未披露 | 定期报告 | 2020-07-31 |
| 2020-07-24 | 6786.75 | 未披露 |
更多>>
1.Class A common shares offered by the company 5,952,381 Class A common shares.
2.Concurrent private placement: One or more entities affiliated with Baker Bros. Advisors have agreed to purchase 1,428,572 Class A1 common shares in a private placement at a price per share equal to the public offering price of Class A common shares in this offering.
3.The total number of Class A common shares, Class B common shares, Class A1 common shares and Class B1 common shares, respectively, to be outstanding after this offering and the concurrent private placement are based on 25,369,973 Class A common shares, 2,463,011 Class B common shares, 16,595,954 Class A1 common shares and 16,057,618 Class B1 common shares, respectively, outstanding as of June 30, 2020.
|
2020-07-24 |
| 2020-08-04 | 6048.66 | 未披露 |
更多>>
from March 31, 2020 to June 30, 2020
Issuance of Class A common shares upon completion of follow-on offering, inclusive of the over-allotment option exercise, net of underwriting discounts and commissions and other offering costs
Issuance of Class A1 common shares upon completion of private placement, net of placement agent fees
Issuance of Class A common shares in connection with the release of escrow from the acquisition of all issued and outstanding equity securities of Primatope Therapeutics, Inc.
Exercise of options and issuance of shares under the employee share purchase plan
|
2020-06-30 |
| 2020-05-04 | 5580.17 | 未披露 | 定期报告 | 2020-04-30 |
| 2020-04-28 | 5575.67 | 未披露 | 定期报告 | 2020-04-22 |
| 2020-05-04 | 5558.14 | 未披露 |
更多>>
From December 31, 2019 to March 31, 2020
Exercise of options
|
2020-03-31 |
| 2020-03-05 | 5554.74 | 未披露 | 定期报告 | 2020-02-29 |
| 2020-03-05 | 5493.76 | 未披露 |
更多>>
from December 31, 2018 to December 31, 2019
Issuance of Class A common shares upon completion of follow-on offering, inclusive of the over-allotment option exercise, net of underwriting discounts and commissions and offering costs
Issuance of Class A1 common shares upon completion of private placement, net of underwriting discounts and commissions and offering costs
Class A common shares issued or to be issued in connection with the acquisition of all issued and outstanding equity securities of Primatope Therapeutics, Inc.
Class A common shares issued or to be issued in connection with a milestone payment due to Primatope Therapeutics, Inc.
Exercise of options and issuance of shares under the employee share purchase plan
|
2019-12-31 |
| 2019-11-05 | 5488.13 | 未披露 | 定期报告 | 2019-10-31 |
| 2019-11-05 | 5487.13 | 未披露 |
更多>>
from June 30, 2019 to September 30, 2019
Exercise of options
|
2019-09-30 |
| 2019-08-13 | 5485.77 | 未披露 |
更多>>
From March 31, 2019 to June 30, 2019
Class A common shares issued or to be issued in connection with a milestone payment due to Primatope Therapeutics, Inc.
Exercise of options and issuance of shares under the employee share purchase plan
|
2019-06-30 |
| 2019-05-07 | 5470.44 | 未披露 | 定期报告 | 2019-04-30 |
| 2019-04-17 | 5470.28 | 未披露 | 定期报告 | 2019-04-12 |
| 2019-05-07 | 5469.28 | 未披露 |
更多>>
from December 31, 2018 to March 31, 2019
Issuance of Class A common shares upon completion of follow-on offering, inclusive of the over-allotment option exercise, net of underwriting discounts and commissions and offering costs
Issuance of Class A1 common shares upon completion of private placement, net of underwriting discounts and commissions and offering costs
Class A common shares issued or to be issued in connection with the acquisition of all issued and outstanding equity securities of Primatope Therapeutics, Inc.
Exercise of options
|
2019-03-31 |
| 2019-03-12 | 5433.22 | 未披露 | 定期报告 | 2019-03-01 |
| 2019-03-12 | 4948.96 | 未披露 |
更多>>
from December 31, 2017 to December 31, 2018
Issuance of Series C convertible preferred shares, net of issuance costs of $9,178
Conversion of convertible preferred shares to common shares
Issuance of Class A common shares upon completion of initial public offering, net of underwriting discounts and commissions and offering costs
Exercise of options and issuance of shares under the employee share purchase plan
|
2018-12-31 |
| 2018-11-06 | 4946.63 | 未披露 | 定期报告 | 2018-10-31 |
| 2018-11-06 | 4946.47 | 2288.55 |
更多>>
from December 31, 2017 to September 30, 2018
Issuance of Series C convertible preferred shares, net of issuance costs of $9,178
Conversion of convertible preferred shares to common shares
Issuance of Class A common shares upon completion of initial public offering, net of underwriting discounts and commissions and offering costs
Exercise of options
|
2018-09-30 |
| 2018-08-06 | 4945.47 | 未披露 | 定期报告 | 2018-07-31 |
| 2018-08-06 | 4944.72 | 未披露 |
更多>>
from December 31, 2017 to June 30, 2018
Issuance of Series C convertible preferred shares, net of issuance costs of $9,178
Conversion of convertible preferred shares to common shares
Issuance of Class A common shares upon completion of initial public offering, net of underwriting discounts and commissions and offering costs
Exercise of options
|
2018-06-30 |
| 2018-05-24 | 4844.08 | 未披露 |
更多>>
1.Class A common shares offered 8,477,777 shares
2.The total number of common shares to be outstanding after this offering is based on 6,270,569 Class A common shares and 4,638,855 Class B common shares outstanding as of March 31, 2018
3.a 1-for-2.73235 reverse share split of our common and preferred shares effected on May 11, 2018
|
2018-05-24 |
| 2018-04-27 | 1172.97 | 9746.33 |
更多>>
from December 31, 2017 to March 31, 2018
Issuance of Series C convertible preferred shares, net of issuance costs of $9,178
Exercise of options
|
2018-03-31 |
From December 31, 2024 to December 31, 2025
Issuance of Class A ordinary shares under incentive award plans and employee share purchase plan
From June 30, 2025 to September 30, 2025
Issuance of Class A ordinary shares under incentive award plans
From March 31, 2025 to June 30, 2025
Issuance of Class A ordinary shares under incentive award plans
From December 31, 2024 to March 31, 2025
Issuance of Class A ordinary shares under incentive award plans
From December 31, 2023 to December 31, 2024
Issuance of Class A ordinary shares under incentive award plans and employee share purchase plan
From June 30, 2024 to September 30, 2024
Issuance of Class A ordinary shares under incentive award plans
From December 31, 2023 to March 31, 2024
Issuance of Class A common shares under incentive award plans
From December 31, 2022 to December 31, 2023
Issuance of Class A common shares under incentive award plans and employee share purchase plan
From June 30, 2023 to September 30, 2023
Issuance of Class A common shares under incentive award plans
From March 31, 2023 to June 30, 2023
Issuance of Class A common shares under incentive award plans
From December 31, 2022 to March 31, 2023
Issuance of Class A common shares under incentive award plans
From December 31, 2021 to December 31, 2022
Issuance of Class A common shares under incentive award plans and employee share purchase plan
From June 30, 2022 to September 30, 2022
Issuance of Class A common shares under incentive award plans
From March 31, 2022 to June 30, 2022
Issuance of Class A common shares under incentive award plans
From December 31, 2021 to March 31, 2022
Issuance of Class A common shares under incentive award plans
From December 31, 2020 to December 31, 2021
Issuance of Class A common shares under incentive award plans and employee share purchase plan
From June 30, 2021 to September 30, 2021
Issuance of Class A common shares under incentive award plans and employee share purchase plan
From March 31, 2021 to June 30, 2021
Issuance of Class A common shares under incentive award plans
From December 31, 2020 to March 31, 2021
Issuance of Class A common shares under incentive award plans
From December 31,2019 to December 31,2020
Issuance of Class A common shares upon completion of follow-on offerings, inclusive of the over-allotment option exercise, net of underwriting discounts and commissions and other offering costs
Issuance of Class A1 common shares upon completion of private placements, net of placement agent fees
Issuance of Class A common shares in connection with the release of escrow from the acquisition of all issued and outstanding equity securities of Primatope Therapeutics, Inc.
Issuance of Class A common shares under incentive award plans and employee share purchase plan
from June 30, 2020 to September 30, 2020
Issuance of Class A common shares upon completion of follow-on offering, net of underwriting discounts and commissions and other offering costs
Issuance of Class A1 common shares upon completion of private placement, net of placement agent fees
Issuance of Class A common shares in connection with the release of shares in connection with a milestone previously paid to Primatope Therapeutics, Inc.
Exercise of options
1.Class A common shares offered by the company 5,952,381 Class A common shares.
2.Concurrent private placement: One or more entities affiliated with Baker Bros. Advisors have agreed to purchase 1,428,572 Class A1 common shares in a private placement at a price per share equal to the public offering price of Class A common shares in this offering.
3.The total number of Class A common shares, Class B common shares, Class A1 common shares and Class B1 common shares, respectively, to be outstanding after this offering and the concurrent private placement are based on 25,369,973 Class A common shares, 2,463,011 Class B common shares, 16,595,954 Class A1 common shares and 16,057,618 Class B1 common shares, respectively, outstanding as of June 30, 2020.
from March 31, 2020 to June 30, 2020
Issuance of Class A common shares upon completion of follow-on offering, inclusive of the over-allotment option exercise, net of underwriting discounts and commissions and other offering costs
Issuance of Class A1 common shares upon completion of private placement, net of placement agent fees
Issuance of Class A common shares in connection with the release of escrow from the acquisition of all issued and outstanding equity securities of Primatope Therapeutics, Inc.
Exercise of options and issuance of shares under the employee share purchase plan
From December 31, 2019 to March 31, 2020
Exercise of options
from December 31, 2018 to December 31, 2019
Issuance of Class A common shares upon completion of follow-on offering, inclusive of the over-allotment option exercise, net of underwriting discounts and commissions and offering costs
Issuance of Class A1 common shares upon completion of private placement, net of underwriting discounts and commissions and offering costs
Class A common shares issued or to be issued in connection with the acquisition of all issued and outstanding equity securities of Primatope Therapeutics, Inc.
Class A common shares issued or to be issued in connection with a milestone payment due to Primatope Therapeutics, Inc.
Exercise of options and issuance of shares under the employee share purchase plan
from June 30, 2019 to September 30, 2019
Exercise of options
From March 31, 2019 to June 30, 2019
Class A common shares issued or to be issued in connection with a milestone payment due to Primatope Therapeutics, Inc.
Exercise of options and issuance of shares under the employee share purchase plan
from December 31, 2018 to March 31, 2019
Issuance of Class A common shares upon completion of follow-on offering, inclusive of the over-allotment option exercise, net of underwriting discounts and commissions and offering costs
Issuance of Class A1 common shares upon completion of private placement, net of underwriting discounts and commissions and offering costs
Class A common shares issued or to be issued in connection with the acquisition of all issued and outstanding equity securities of Primatope Therapeutics, Inc.
Exercise of options
from December 31, 2017 to December 31, 2018
Issuance of Series C convertible preferred shares, net of issuance costs of $9,178
Conversion of convertible preferred shares to common shares
Issuance of Class A common shares upon completion of initial public offering, net of underwriting discounts and commissions and offering costs
Exercise of options and issuance of shares under the employee share purchase plan
from December 31, 2017 to September 30, 2018
Issuance of Series C convertible preferred shares, net of issuance costs of $9,178
Conversion of convertible preferred shares to common shares
Issuance of Class A common shares upon completion of initial public offering, net of underwriting discounts and commissions and offering costs
Exercise of options
from December 31, 2017 to June 30, 2018
Issuance of Series C convertible preferred shares, net of issuance costs of $9,178
Conversion of convertible preferred shares to common shares
Issuance of Class A common shares upon completion of initial public offering, net of underwriting discounts and commissions and offering costs
Exercise of options
1.Class A common shares offered 8,477,777 shares
2.The total number of common shares to be outstanding after this offering is based on 6,270,569 Class A common shares and 4,638,855 Class B common shares outstanding as of March 31, 2018
3.a 1-for-2.73235 reverse share split of our common and preferred shares effected on May 11, 2018
from December 31, 2017 to March 31, 2018
Issuance of Series C convertible preferred shares, net of issuance costs of $9,178
Exercise of options